1. Home
  2. DSL vs AVLN Comparison

DSL vs AVLN Comparison

Compare DSL & AVLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo DoubleLine Income Solutions Fund of Beneficial Interests

DSL

DoubleLine Income Solutions Fund of Beneficial Interests

N/A

Current Price

$10.54

Market Cap

1.2B

Sector

Finance

ML Signal

N/A

Logo Avalyn Pharma Inc. Common Stock

AVLN

Avalyn Pharma Inc. Common Stock

N/A

Current Price

$35.33

Market Cap

1.3B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
DSL
AVLN
Founded
2013
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.3B
IPO Year
2013
2026

Fundamental Metrics

Financial Performance
Metric
DSL
AVLN
Price
$10.54
$35.33
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
546.7K
168.0K
Earning Date
01-01-0001
N/A
Dividend Yield
11.95%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$10.49
$24.90
52 Week High
$12.67
$40.17

Technical Indicators

Market Signals
Indicator
DSL
AVLN
Relative Strength Index (RSI) 43.23 55.36
Support Level $10.53 $34.22
Resistance Level $11.02 $40.08
Average True Range (ATR) 0.10 1.91
MACD -0.00 -0.46
Stochastic Oscillator 12.27 35.63

Price Performance

Historical Comparison
DSL
AVLN

About DSL DoubleLine Income Solutions Fund of Beneficial Interests

DoubleLine Income Solutions Fund is a closed-end management investment company. Its primary investment objective is to seek high income and its secondary objective is to seek capital appreciation. It invests in debt securities and other income-producing investments anywhere in the world, including emerging markets. The company's investment portfolio comprises foreign corporate bonds, U.S. corporate bonds, bank loans, collateralized loan obligations, non-agency commercial mortgage backed obligations, asset-backed obligations, and municipal bonds among others.

About AVLN Avalyn Pharma Inc. Common Stock

Avalyn Pharma Inc is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). Its current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer. Its flagship programs include AP01 and AP02, which are inhaled formulations of pirfenidone and nintedanib being developed for conditions such as progressive pulmonary fibrosis and idiopathic pulmonary fibrosis. The company has one operating and reportable segment, which is the business of developing and commercializing targeted therapies for rare lung diseases.

Share on Social Networks: